Low Dose Oxybutynin in Childhood Nocturnal Enuresis
Journal of Pediatric Nephrology,
Vol. 2 No. 2 (2014),
9 May 2014
,
Page 67-75
https://doi.org/10.22037/jpn.v2i2.5564
Abstract
Introduction: To evaluate the response to low dose oxybutynin in children with nocturnal enuresis.
Materials and Methods: Forty-one neurologically normal enuretic children who were visited in our nephrology clinic in a 3-year period (2007-2009) received low dose oxybutynin (2.5-10 mg/day depending on the weight) to define response to the drug in one and 3- month periods. No, partial, and full response were defined as 0-49%, 50-89% and ≥90% decrease in bed wetting, respectively.
Results: In the first month of treatment, full, partial, and no response were reported in 3 (7.3%), 14 (34.1%), and 24 (58.6%) patients, respectively. In the non-responder patients, 6 (25%) and 5 (20.8 %) patients showed full and partial response in the 3-month period whereas 13 (54.2%) had no response. The side effects of the drug were reported in 5 (12.2%) patients. Children with non-mono symptomatic nocturnal enuresis (NMNE) showed a better response to the drug than those with mono symptomatic nocturnal enuresis (MNE) (75% versus 25%). There was no significant differences in age, gender, family history of enuresis, and the presence or absence of daytime urinary or bowel symptoms between responder and non-responder groups (P>0.05 for all).
Conclusions: In this clinical report study, there was 68.3% treatment benefit and 12% risk (side effects of the drug) with low dose oxybutynin. Therefore, it may have a role in treating nocturnal enuresis, especially in patients with NMNE who experience adverse effects of standard treatment (Higher doses of the drug).
Keywords: Nocturnal Enuresis; Child; Oxybutynin; Risks and Benefits; Adverse effects.
How to Cite
References
Sehgal R, Paul P, Mohanty NK .Urodynamic evaluation in primary enuresis: an investigative andtreatment outcome correlation. Journal of Tropical Pediatrics 2007;53(4):259-263.
Van Hoeck KJ, Bael A, Van Dessel E, et al. Do holding exercises or anti-muscarinics increase maximum voided volume in mono-symptomatic nocturnal enuresis? A randomized controlled trial in children. The journal of urology 2007;178:2132-2137.
Emmanuel K S, Ramesh K.A. Spectrophotometric determination of oxybutynin chloride through ion-association complex formation. Rasayan J Chem 2010; 3(1(:179-187.
Rapporteur’s public paediatric assessment report for paediatric studies. Oxybutynin Hydrochloride (Ditropan, Dridase). UK/W/017/pdWS/001, 2009:1-29.
Neveus T, Lackgren G, Tuvemo T, Hetta J, Hjalmas K ,Stenberg A. Enuresis–background and treatment. Scand J Urol Nephrol 2000; 206:1.
Zaffanello M, Giacomello L, Brugnara M, Fanos V. Therapeutic options in childhood nocturnal enuresis. Minerva Urol Nefrol. 2007;59(2):199-205.
Montaldo p, Tafuro L , Rea M , Narciso V, Iossa AC , Del Gado R. Desmopressin and oxybutynin in Monosymptomatic nocturnal enuresis: a randomized, double - blind, placebo - controlled trial and an assessment of predictive factors. BJUI International 2012;1-6
Lovering JS, Tallett SE, Mc Kendry JB. Oxybutynin efficacy in the treatment of primary enuresis. Pediatrics 1988;82:104.
Neveus T. Oxybutynin, desmopressin and enuresis. J Urol 2001;166(6):2459-62.
Starfield B, Mellits DM. Increase in functional bladder capacity and improvements in enuresis. J Pediatr 1968;72: 483.
De Wachter S, Vermandel A, De Moerloose K, Wyndaele JJ. Value of increase in bladder capacity in treatment of refractory mono-symptomatic nocturnal enuresis in children. Urology 2002; 60:1090.
Hoekx L, Vermandel A, Wyndaele JJ. Functional bladder capacity after bladder biofeedback predicts long-term outcome in children with nocturnal enuresis. Scand J Urol Nephrol 2003;37:120.
Forsythe WI, Redmond A. Enuresis and spontaneous cure rate: study of 1129 enuretics. Arch Dis Child 1974;49:259.
Mammen AA, Ferrer FA. Nocturnal enuresis: medical management. Urol Clin North Am 2004;31(3): 491-8.
Caione P, Arena F, Biraghi M, et al. Nocturnal enuresis and daytime wetting: a multicentre trial with oxybutynin and desmopressin. Eur Urol1997;31(4):459-63.
Naseri M, Hiradfar M. Monosymptomatic and non–monosymptomatic nocturnal enuresis: a clinical evaluation. Arch Iran Med 2012;15(11):702-706.
Naseri M, Hiradfar M. Abnormal Urodynamic Findings in Children with Nocturnal Enuresis. Indian Pediatrics 2012;49:401-403.
Nevéus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract functions in children and adolescents: report from the standardization committee of the international children’s continence society. The journal of urology2006;176:314-324.
Keats TE, Sistrom C. Atlas of radiology measurement, 7th ed, 2001. Mosby, Missouri, pp 461-62.
Hjälmås K. Enuresis in children. Pediatric Urology 2002; 28(3):232-49.
Shroff S, Ramanan SV. Manual of urodynamic. Medindiae publication:15.
Yeung CK, Sit FK, To LK, Chiu HN, Sihoe JD, Lee E, et al. Reduction in nocturnal functional bladder capacity is a common factor in the pathogenesis of refractory nocturnal enuresis. BJU Int 2002;90:302.
Ferrara P, D’Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intra vesical oxybutynin chloride in children with spina bifida. BJU Int2001; 87(7): 674-8.
Haferkamp A, Staehler G, Gerner HJ, Dörsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patient. Spinal Cord 2000;38(4): 250-4.
Gish P, Mosholder AD, Truffa M, Johann-Liang R. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult case.J Pediatr 2009;155(3):432-4.
Butler R, Stenberg A. Treatment of childhood nocturnal enuresis: an examination of clinically relevant principle. BJU Int 2001;88(6):563-71.
Sommer BR, O’Hara R, Askari N, Kraemer HC, Kennedy W. The effect of oxybutynin treatment on cognition in children with diurnal incontinence. J Urol 2005;173(6): 2125-7.
Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 2008; 27(4):315-8.
Baigrie RJ, Kelleher JP, Fawcett D, Pengelly AW. Oxybutynin: is it safe? Br J Urol 1988; 62(4):319-22.
Jonville AP, Dutertre JP, Autret E, Barbellion M. Adverse effects of oxybutynin chloride (Ditropan.(Evaluation of the official survey of regional pharmacovigilance centers. Therapie 1992; 47 (5): 389-92.
Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G . Efficacy and safety of trans- dermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol 2009; 182 (4):1548-54.
Fergusson DM, Horwood MJ. Nocturnal enuresis and behavioral problems in adolescence: a 15-year longitudinal study. Pediatrics 1994;94:662–8.
Feehan M, McGee R, Stanton W, Silvan SR. A six-year follow-up of childhood enuresis: prevalence in adolescence and Consequences for mental health. J Pediatric Child Health 1990;26:75–9.
- Abstract Viewed: 576 times
- PDF Downloaded: 293 times